Corient Private Wealth LP Acquires Shares of 159,262 Artivion, Inc. $AORT

Key Points

• Corient Private Wealth acquired 159,262 Artivion shares in the second quarter, worth approximately $3.58 million and representing 0.33% of the company. Institutional investors collectively own 86.37% of Artivion.
• Artivion reported quarterly EPS of $0.13 and revenue of $125.76 million, exceeding analysts’ $119.99 million estimate. Shares opened at $27.04, well below the consensus analyst price target of $44.83.
• Analyst sentiment remains broadly positive, with seven Buy ratings and one Sell rating, although insiders sold 114,978 shares worth about $2.97 million over the past 90 days.

Corient Private Wealth LP bought a new position in Artivion, Inc. (NYSE:AORT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 159,262 shares of the company's stock, valued at approximately $3,579,000. Corient Private Wealth LP owned 0.33% of Artivion at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion during the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. lifted its position in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock worth $30,000 after purchasing an additional 399 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock worth $43,000 after purchasing an additional 563 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after purchasing an additional 538 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in Artivion during the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Price Performance

Shares of NYSE:AORT opened at $27.04 on Wednesday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -386.23 and a beta of 1.25. The business has a 50-day moving average of $25.90 and a two-hundred day moving average of $29.41. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, equities research analysts predict that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of research analyst reports. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. Weiss Ratings cut shares of Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Canaccord Genuity Group increased their price objective on Artivion from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Finally, Wall Street Zen cut Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Artivion presently has an average rating of "Moderate Buy" and a consensus price target of $44.83.

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of the firm's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO James P. Mackin sold 70,000 shares of Artivion stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 114,978 shares of company stock valued at $2,965,155 over the last 90 days. 6.30% of the stock is currently owned by company insiders.

Artivion Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source